Fennec Pharmaceuticals Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.04 Intrinsic Value $16.10median of 2 methodsbased on filings through 30 Jun 2026 Market Price $10.33Price as of 1 Oct 2026 Significantly undervaluedIntrinsic value is 56% above the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (+56%) Data confidence Sign in to view data confidence Market Cap $362.2M Enterprise Value $340.4M Shares Outstanding 38.4M diluted Next Earnings Date12 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Fennec Pharmaceuticals is transitioning into a high-growth commercial-stage specialty pharmaceutical company, driven by its sole FDA-approved product, PEDMARK (sodium thiosulfate injection). PEDMARK is uniquely positioned as the first and only approved therapy to reduce the risk of cisplatin-induced ototoxicity in pediatric patients. Recent financial results demonstrate strong commercial execution, with Q1 2026 net product sales surging 73% year-over-year to $15.1 million, driven by expanded market penetration and successful targeting of the adolescent and young adult (AYA) population. With a settled patent litigation extending market exclusivity to at least September 2033 and an active commercial partnership with Norgine in Europe, Australia, and New Zealand, Fennec is well-positioned to capture a highly specialized, high-margin oncology niche. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$13.00 Mean target$15.67 High · most bullish analyst$18.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The bear case assumes slower-than-expected commercial uptake in the AYA market, high commercialization expenses that pressure operating margins, or potential long-term competitive threats from alternative protective agents or generic entrants if patent protections are challenged. Base CaseCentral scenario The base case assumes continued steady adoption of PEDMARK in pediatric and AYA oncology centers, supported by the expanded 24-territory sales force. Exclusivity is secured through 2033 following the Cipla settlement, and international royalties from Norgine begin to contribute meaningfully. Operating cash flows remain positive, eliminating the near-term need for dilutive financing. Bull CaseUpside scenario Fennec's bull case centers on the commercial execution of PEDMARK (the first and only FDA-approved therapy to reduce cisplatin-induced ototoxicity in pediatric patients) and its strategic expansion into the larger Adolescent and Young Adult (AYA) and adult oncology supportive-care markets, supported by a robust debt-free balance sheet. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |